Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2021 | Current state of the art for WM

Jorge Castillo • 16 Apr 2021
COMy 2021
Lymphoma Rare Diseases Waldenström’s Macroglobulinemia Acalabrutinib Bendamustine Bortezomib Carfilzomib Cyclophosphamide Ibrutinib Ixazomib Zanubrutinib

Chemoimmunotherapy represents a tried a tested approach to Waldenström’s macroglobulinemia (WM). Jorge Castillo, MD, Dana-Farber Cancer Institute, Boston, MA, talks on the current state of the art for WM management, commenting on the increasing number of agents physicians have at their disposal and the subsequent positive impact this has on patient outcomes. This interview took place during the 7th World Congress on Controversies in Multiple Myeloma (COMy), 2021.

Disclosures

Jorge Castillo receives research funds and/or honoraria from Abbvie, Beigene, Janssen, Pharmacyclics, Roche, TG Therapeutics

More from Jorge Castillo

2:22
Real-world outcomes following dose reduction of first-line ibrutinib in patients with WM
Jorge Castillo • 10 Dec 2023
2:27
Acalabrutinib plus rituximab for treating anti-MAG mediated IgM peripheral neuropathy in WM
Jorge Castillo • 10 Dec 2023
3:03
Outcomes following venetoclax monotherapy in patients with R/R WM in the real-world setting
Jorge Castillo • 10 Dec 2023
3:32
Research updates in WM from ASH 2023
Jorge Castillo • 10 Dec 2023

Related Videos

0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:37
Exciting CAR-T clinical trials in LBCL and FL
Gloria Iacoboni • 15 Apr 2024
0:59
The common clinical manifestations of BPDCN
Anthony Stein • 15 Apr 2024
1:48
Novel immunotherapy approaches in lymphoma: CAR-T cells, bispecifics & sequencing
Gloria Iacoboni • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals